A detailed history of Virtus ETF Advisers LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 50,747 shares of ARDX stock, worth $262,869. This represents 0.17% of its overall portfolio holdings.

Number of Shares
50,747
Previous 50,747 -0.0%
Holding current value
$262,869
Previous $376,000 7.18%
% of portfolio
0.17%
Previous 0.19%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.31 $210,903 - $333,363
35,807 Added 239.67%
50,747 $376,000
Q1 2024

May 15, 2024

SELL
$6.05 - $9.74 $6,183 - $9,954
-1,022 Reduced 6.4%
14,940 $109,000
Q4 2023

Feb 15, 2024

SELL
$3.29 - $6.64 $28,402 - $57,323
-8,633 Reduced 35.1%
15,962 $98,000
Q3 2023

Nov 07, 2023

SELL
$3.3 - $4.83 $8,098 - $11,852
-2,454 Reduced 9.07%
24,595 $100,000
Q2 2023

Aug 14, 2023

BUY
$3.23 - $4.95 $87,368 - $133,892
27,049 New
27,049 $91,000
Q4 2021

Feb 14, 2022

SELL
$0.86 - $1.7 $24,676 - $48,779
-28,694 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$1.27 - $8.17 $1,896 - $12,197
-1,493 Reduced 4.95%
28,694 $38,000
Q2 2021

Aug 10, 2021

SELL
$6.55 - $8.98 $88,176 - $120,888
-13,462 Reduced 30.84%
30,187 $229,000
Q1 2021

May 17, 2021

BUY
$6.1 - $7.69 $4,690 - $5,913
769 Added 1.79%
43,649 $289,000
Q4 2020

Feb 12, 2021

SELL
$5.05 - $7.1 $19,669 - $27,654
-3,895 Reduced 8.33%
42,880 $277,000
Q3 2020

Nov 13, 2020

SELL
$5.25 - $7.08 $33,516 - $45,198
-6,384 Reduced 12.01%
46,775 $246,000
Q2 2020

Aug 05, 2020

BUY
$5.37 - $8.11 $9,666 - $14,597
1,800 Added 3.5%
53,159 $368,000
Q1 2020

May 14, 2020

SELL
$4.35 - $8.79 $32,594 - $65,863
-7,493 Reduced 12.73%
51,359 $292,000
Q4 2019

Feb 13, 2020

BUY
$4.23 - $8.29 $248,943 - $487,883
58,852 New
58,852 $442,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $801M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.